However, in most instances, the ICI utilized for re-initiation in NSCLC could be the same ICIs used before, another PD-1/PD-L1 inhibitors, or the switching from PD-1 to PD-L1 inhibitors or the converse (160–164). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.